Clinical Trial: ALLIANCE A092205

ALLIANCE A092205

Status: New, Open

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease

Eligible for screening study DCP 001